Gyrus gets US nod for RF (radiofrequency) tonsil treatment:
This article was originally published in Clinica
Executive Summary
Gyrus has received US FDA 510(k) marketing clearance to use its Gyrus ENT Somnoplasty system for tonsil reduction in teenagers and adults. The minimally invasive method uses temperature controlled radiofrequency energy to reduce obstructive symptoms in enlarged tonsils. The Reading, UK-based firm already has US clearance to use the system in the treatment of obstructive sleep apnoea, chronic nasal obstruction and habitual snoring. The latest clearance provides another step in broadening the opportunity for the firm in the $1bn head and neck surgery market, says the company.